Lacking genuinely new medicines or definitive proof that their costly, patented drugs work better than cheap ones, producers are forced to turn minormarketing advantages into billion-dollar opportunities.
While such forces have played a minor role for Groupon, issues of software elegance and interface sophistication matter far less than simply managing marketing and growth.